BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sikov WM, Dizon DS, Strenger R, Legare RD, Theall KP, Graves TA, Gass JS, Kennedy TA, Fenton MA. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol. 2009;27:4693-4700. [PMID: 19720916 DOI: 10.1200/jco.2008.21.4163] [Cited by in Crossref: 78] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, Orr N, Parton M, Smith IE, Reis-Filho JS, Dowsett M, Ashworth A, Turner NC. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010;16:6159-68. [PMID: 20802015 DOI: 10.1158/1078-0432.CCR-10-1027] [Cited by in Crossref: 210] [Cited by in F6Publishing: 113] [Article Influence: 17.5] [Reference Citation Analysis]
2 Minami CA, Chung DU, Chang HR. Management options in triple-negative breast cancer. Breast Cancer (Auckl) 2011;5:175-99. [PMID: 21863131 DOI: 10.4137/BCBCR.S6562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
3 Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33:13-21. [PMID: 25092775 DOI: 10.1200/jco.2014.57.0572] [Cited by in Crossref: 458] [Cited by in F6Publishing: 238] [Article Influence: 57.3] [Reference Citation Analysis]
4 Dębska-Szmich S, Krakowska M, Czernek U, Habib-Lisik M, Zięba A, Potemski P. The role of preoperative systemic treatment in patients with breast cancer. Contemp Oncol (Pozn) 2016;20:93-101. [PMID: 27358586 DOI: 10.5114/wo.2016.60067] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Ratanaphan A, Canyuk B. Host Cell Reactivation and Transcriptional Activation of Carboplatin-Modified BRCA1. Breast Cancer (Auckl) 2014;8:51-6. [PMID: 24678242 DOI: 10.4137/BCBCR.S14224] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Jenkins S, Kachur ME, Rechache K, Wells JM, Lipkowitz S. Rare Breast Cancer Subtypes. Curr Oncol Rep 2021;23:54. [PMID: 33755810 DOI: 10.1007/s11912-021-01048-4] [Reference Citation Analysis]
7 Adams S, Chakravarthy AB, Donach M, Spicer D, Lymberis S, Singh B, Bauer JA, Hochman T, Goldberg JD, Muggia F, Schneider RJ, Pietenpol JA, Formenti SC. Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Res Treat 2010;124:723-32. [PMID: 20878462 DOI: 10.1007/s10549-010-1181-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
8 Hirsh RL, DeMichele A. The role of lapatinib in the preoperative therapy of breast cancer. Curr Oncol Rep 2012;14:44-7. [PMID: 22037924 DOI: 10.1007/s11912-011-0206-8] [Reference Citation Analysis]
9 Ratanaphan A. A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer. Int J Mol Sci 2012;13:14898-916. [PMID: 23203101 DOI: 10.3390/ijms131114898] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
10 Yu KD, Liu GY, Chen CM, Li JW, Wu J, Lu JS, Shen ZZ, Shao ZM. Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule. Oncologist 2013;18:511-7. [PMID: 23635560 DOI: 10.1634/theoncologist.2012-0057] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
11 Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 2012;118:2385-93. [PMID: 21953213 DOI: 10.1002/cncr.26555] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
12 Aigner B, Plötz SG, Schaller G. Triple-negative breast cancer possibly transforming into malignant melanoma due to targeted therapy? A case report and review of literature. Wien Med Wochenschr 2013;163:495-8. [PMID: 24221053 DOI: 10.1007/s10354-013-0242-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Jagosky M, Tan AR. Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data. Breast Cancer (Dove Med Press) 2021;13:393-407. [PMID: 34163239 DOI: 10.2147/BCTT.S176514] [Reference Citation Analysis]
14 Piccart M, Viale G, Ellis P, Abramowicz M, Carey L. Tips and tricks in triple-negative breast cancer: how to manage patients in real-life practice? Ecancermedicalscience 2011;5:217. [PMID: 22276059 DOI: 10.3332/ecancer.2011.217] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Natoli C, Vici P, Sperduti I, Grassadonia A, Bisagni G, Tinari N, Michelotti A, Zampa G, Gori S, Moscetti L, De Tursi M, Panebianco M, Mauri M, Ferrarini I, Pizzuti L, Ficorella C, Samaritani R, Mentuccia L, Iacobelli S, Gamucci T. Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. J Cancer Res Clin Oncol 2013;139:1229-40. [PMID: 23604446 DOI: 10.1007/s00432-013-1436-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
16 Sardesai S, Badawi M, Mrozek E, Morgan E, Phelps M, Stephens J, Wei L, Kassem M, Ling Y, Lustberg M, Stover D, Williams N, Layman R, Reinbolt R, VanDeusen J, Cherian M, Grever M, Carson W, Ramaswamy B, Wesolowski R. A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. Invest New Drugs 2020;38:1400-10. [PMID: 31953695 DOI: 10.1007/s10637-020-00895-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
17 Gruver AM, Peerwani Z, Tubbs RR. Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J Clin Pathol 2010;63:210-9. [PMID: 20203220 DOI: 10.1136/jcp.2009.062760] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
18 Rangel N, Forero-Castro M, Rondón-Lagos M. New Insights in the Cytogenetic Practice: Karyotypic Chaos, Non-Clonal Chromosomal Alterations and Chromosomal Instability in Human Cancer and Therapy Response. Genes (Basel) 2017;8:E155. [PMID: 28587191 DOI: 10.3390/genes8060155] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
19 Kolberg HC, Akpolat-Basci L, Stephanou M, Aktas B, Hannig CV, Liedtke C. Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years. Breast Care (Basel) 2016;11:323-7. [PMID: 27920624 DOI: 10.1159/000452079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
20 Bozza C, Osa EO, Puglisi F. Primary therapy in breast cancer: what have we learned from landmark trials? Womens Health (Lond) 2013;9:583-93. [PMID: 24161310 DOI: 10.2217/whe.13.55] [Reference Citation Analysis]
21 Mrózek E, Layman R, Ramaswamy B, Lustberg M, Vecchione A, Knopp MV, Shapiro CL. Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer. Clin Breast Cancer 2014;14:228-34. [PMID: 24703985 DOI: 10.1016/j.clbc.2014.02.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
22 Connolly RM, Stearns V. Current approaches for neoadjuvant chemotherapy in breast cancer. Eur J Pharmacol 2013;717:58-66. [PMID: 23545358 DOI: 10.1016/j.ejphar.2013.02.057] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
23 Gao Z, Xu J, Wang Y, Wu J, Sun T. Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant. Front Oncol 2021;11:715554. [PMID: 34722261 DOI: 10.3389/fonc.2021.715554] [Reference Citation Analysis]
24 Aogi K, Saeki T, Nakamura S, Kashiwaba M, Sato N, Masuda N, Rai Y, Ohno S, Kuroi K, Nishimura R, Miyakoda K, Akiyama F, Kurosumi M, Ikeda T. A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study). Int J Clin Oncol 2013;18:598-606. [PMID: 22833344 DOI: 10.1007/s10147-012-0437-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Shinde AM, Zhai J, Yu KW, Frankel P, Yim JH, Luu T, Kruper L, Vito C, Shaw S, Vora NL, Kirschenbaum M, Somlo G. Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab. Breast 2015;24:18-23. [PMID: 25467313 DOI: 10.1016/j.breast.2014.10.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
26 Chowdhury P, Ghosh U, Samanta K, Jaggi M, Chauhan SC, Yallapu MM. Bioactive nanotherapeutic trends to combat triple negative breast cancer. Bioact Mater 2021;6:3269-87. [PMID: 33778204 DOI: 10.1016/j.bioactmat.2021.02.037] [Reference Citation Analysis]
27 Yin Y, Zhang P, Xu BH, Zhang BL, Li Q, Yuan P, Cai RG, Wang JY, Wang X, Xu XZ. Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer. J Huazhong Univ Sci Technolog Med Sci 2013;33:262-5. [PMID: 23592141 DOI: 10.1007/s11596-013-1108-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
28 Omarini C, Guaitoli G, Pipitone S, Moscetti L, Cortesi L, Cascinu S, Piacentini F. Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. Cancer Manag Res 2018;10:91-103. [PMID: 29391830 DOI: 10.2147/CMAR.S146658] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
29 Wu K, Yang Q, Liu Y, Wu A, Yang Z. Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy. World J Surg Oncol 2014;12:95. [PMID: 24731479 DOI: 10.1186/1477-7819-12-95] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
30 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014; 5(2): 125-133 [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 9.4] [Reference Citation Analysis]
31 Huang L, Liu Q, Chen S, Shao Z. Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer. Onco Targets Ther 2017;10:5739-44. [PMID: 29238206 DOI: 10.2147/OTT.S145934] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
32 Ademuyiwa FO, Ellis MJ, Ma CX. Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer. J Oncol 2013;2013:219869. [PMID: 23983689 DOI: 10.1155/2013/219869] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
33 Sikov WM. Assessing the role of platinum agents in aggressive breast cancers. Curr Oncol Rep 2015;17:3. [PMID: 25665554 DOI: 10.1007/s11912-014-0428-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
34 Ding J, Yang Y, Jiang L, Wu W, Shao Z. Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab. Oncotarget 2017;8:56626-34. [PMID: 28915617 DOI: 10.18632/oncotarget.17993] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]